RESEARCH MONOGRAPH · KDC-MN-392
Trenbolone
Trenbolone is a 19-nortestosterone derivative with an extra 11-dehydro double bond, originally approved as a cattle growth implant (Finaplix). It is one of the most potent anabolic steroids ever made: it binds the androgen receptor with affinity comparable to testosterone but with greater intrinsic activity, the 19-nor structure prevents aromatization to estrogen, and the 11-dehydro modification blocks the 5-alpha-reduction step that normally limits AR engagement. The combination produces dramatic anabolic effects paired with an unusually rough side-effect profile: paradoxical gynecomastia (via progesterone receptor activation), drenching night sweats, insomnia, anxiety, and putative kidney stress. Schedule III. Used as the canonical high-potency AAS reference in research. Not stocked by Kodiac. This monograph is provided for research and educational reference.
Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.
19-nor 11-dehydro AAS (high-potency)
A 19-nortestosterone-derived 11-dehydro AAS; one of the most potent AAS used in cattle (Finaplix) and diverted to non-medical use.
Abstract
Trenbolone (17-beta-hydroxyestra-4,9,11-trien-3-one; CAS 10161-33-8; molecular formula C18H22O2; molecular weight 270.37) is a 19-nortestosterone-derived 11-dehydro AAS approved for veterinary use as growth-promoting cattle implant (Finaplix). The compound is among the highest-potency AAS at the androgen receptor (Ki approximately 0.5 nM, comparable to testosterone with greater intrinsic activity); the 19-nor structure prevents aromatization to estrogen, and the 11-dehydro double bond prevents 5-alpha-reduction to a more potent metabolite (the AR-active form is trenbolone itself). The AR potency combined with progesterone receptor activity produces pronounced anabolic effects with significant adverse profile: gynecomastia (paradoxical, via progestogenic activity), dramatic sweating, sleep disturbance, anxiety, and putative kidney stress. Plasma half-life of native trenbolone is short (hours); the acetate, enanthate, and hexahydrobenzylcarbonate ester forms used non-medically range from days to weeks. Schedule III in the US. Used as a high-potency reference AAS in research.
Mechanism of action
19-nortestosterone 11-dehydro AAS; high-potency AR agonist with PR activity. No aromatization; no 5-alpha-reduction.
Reported research dose ranges
Reported research dose ranges vary across the published literature.
References
- Yarrow JF, et al. Trenbolone enanthate effects on body composition and muscle protein synthesis. J Steroid Biochem Mol Biol 2010.
- Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008.
- Llewellyn W. Anabolics. Body of Science 2011.
Read the full monograph
Available as a research-use-only PDF download.
The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.
FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.